A Holistic study on demographics and cardiac imaging in cardiac implantable electronic device users
Research Article
Keywords:
Cardiac Implantable Electronic Device, Cardiac Resynchronization Therapy, Complete Heart Block, ECG abnormalities, Implantable Cardioverter Defibrillator, Left Ventricular Ejection FractionAbstract
Worldwide there were reportedly 1.14 million pacemaker implantations starting around 2022. The number is supposed to ascend by 1.48 million by the year 2027. The remarkable ascent in pacemaker implantation throughout the course of recent many years might be credited to the aging population and the extension of pacing signs, for example, complete heart block and congestive cardiovascular breakdown. The embedded cardiovascular pacemakers have progressed from clear, non-programmable, non-coordinated ventricular pacing to complex multi-programmed double chamber and biventricular gadgets. We conducted single centered focused, ambi-directional, cross-sectional study in a Tertiary care hospital, Kakinada with the data of 118 subjects for a review time of 1 year. 112 were signed up for our review while the leftover 6 were passing cases and individuals with positively no interest in cooperation. Among 112 subjects, the larger part 38 (40%) subjects were determined to have Total heart block followed by Congestive cardiovascular breakdown 27 (24%). According to ECG irregularities, 41 (37%) subjects had total AV block followed by 36 (32%) subjects who were determined to have sick sinus syndrome. The subjects with severe left ventricular ejection fraction are highly recommended to go through gadget implantation straightaway. The number of patients getting long-lasting pacemakers, Implantable Cardioverter defibrillators, and cardiovascular resynchronization treatments has expanded as a result of advancements that save lives, improve the quality of life and lower mortality
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Pharma Insights and Research

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.